Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia

Pharmacotherapy

Volumn 20, Issue 8 I, 2000, Pages 950-957

  Brophy, Donald F ^a   Wallace, Joel F ^b,c   Kennedy, Daniel T ^a   Gehr, Todd W B ^a   Holdford, David A ^a  

^a Departments of Pharmacy and Internal Medicine Nephrology   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Zynx Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CALCIUM CARBONATE; LOW DENSITY LIPOPROTEIN; SEVELAMER;

ARTICLE; CHRONIC KIDNEY FAILURE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; HYPERPHOSPHATEMIA;

ANTILIPEMIC AGENTS; CALCIUM CARBONATE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EPOXY COMPOUNDS; HEALTH CARE COSTS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL; PHOSPHATES; POLYAMINES; POLYETHYLENES; PYRROLES;

EID: 0033842543     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.11.950.35261     Document Type: Article

References (0)